Department of Biomedical Sciences, SNU

Faculty

Faculty

Research

Research Field
A. Alzheimer's Disease Prevention Laboratory
Degenerative neurological disease, Alzheimer's disease, proteomics, diagnostic markers, cerebral neural network/plasticity
B. Alzheimer's disease (AD) is a degenerative neurological disease that is rapidly increasing in number with aging populations. The study of the molecular illness of AD is a very important field of research in providing molecular targets for patient care and diagnosis. In this laboratory, we attempt to study the molecular vials of these ADs using a variety of perspectives and different experimental techniques.
(1) A study on the cross-talk between nerve-neurogastric cells in Alzheimer's disease
(2) A study on the correlation between mitochondrial dysfunction and Alzheimer's disease
(3) A Study on the Role of RAGE in Brain Aging and AD
(4) A study on the correlation between cholesterol and glucose metabolism and Alzheimer's disease
(5) A Study on the Relationship between the Immune System and Alzheimer's Disease
(6) Deriving biological markers for AD diagnosis
These studies use molecular, cytobiological, and genetic methods in addition to molecular imaging techniques such as two photon microscope, microfluidics, functional proteomics, and gene knockdown methods at the cell and population levels using siRNA virus systems.
Keyword
Neurodegenerative diseases, Alzheimer’s disease, proteomics, proteases, brain aging

Education

  • 1982~1986 B.S., Seoul National University (Molecular biology)
  • 1991~1995 Ph.D.,University of Arizona, U.S.A. Department of Cell Biology & Anatomy Division of Developmental Neurobiology

Career

  • 1995~1996 Post-doc, UC San Diego (Neuroscience)
  • 1996~2003 Assistant/Associate Professor, Ajou University School of Medicine Brain Disease Research Center/Department of Anatomy
  • 2004~Present Associate Professor/Professor, Dept. Biochemistry & Biomedical Sciences, Seoul National University College of Medicine

Publication

  1. A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease. Cell Metab. 2019 Sep 3;30(3):493-507.e6. doi: 10.1016/j.cmet.2019.06.005. Epub 2019 Jun 27.
  2. Prognostic plasma protein panel for Aβ deposition in the brain in Alzheimer's disease. Prog Neurobiol. 2019 Dec;183:101690. doi: 10.1016/j.pneurobio.2019.101690. Epub 2019 Oct 9.
  3. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model. Gut. 2020 Feb;69(2):283-294. doi: 10.1136/gutjnl-2018-317431. Epub 2019 Aug 30.
  4. A logical network-based drug-screening platform for Alzheimer's disease representing pathological features of human brain organoids. Nat Commun. 2021 Jan 12;12(1):280. doi: 10.1038/s41467-020-20440-5.
  5. Plexin-A4 mediates amyloid-β-induced tau pathology in Alzheimer's disease animal model. Prog Neurobiol. 2021 Aug;203:102075. doi: 10.1016/j.pneurobio.2021.102075. Epub 2021 May 15.